Kornimate/medical-research-clean huggingface dataset:
should colon or non-colon originated lesions be distinguished?

Conditions: Acute Lower Gastrointestinal Dysfunction

Summary: this prospective study was designed to compare the difference of effects of conventional treatment, medicine intervention, endoscopic therapy, and surgery between colon originated and non-colon originated algid in critical patients, in order to alert doctors to differ the treatment of the two algid and provide basis for treatment.


Eligibility criteria:
inclusion criteria: 1. patients in our icu aged 18-75 years. 2. patients with a confirmed diagnosis of algid. exclusion criteria: 1. mechanical intestinal obstruction (including tumor, stercoral obstruction etc.) 2. gastrointestinal hemorrhage within 72 hours. 3. history of inflammatory bowel disease (ulcerative colitis or crohn's disease) or radiation enteritis. 4. pregnancy. 5. contraindications of neostigmine administration.

Keywords: acute lower gastrointestinal dysfunction colon-originated lesions critical patient colonoscopic decompression anticholinergic drugs
consequences of covid 19 pandemic on childhood asthma

Conditions: Asthma in Children

Summary: the sars-cov2 pandemic, which emerged in the first quarter of 2020, has led to an unprecedented health crisis in our modern healthcare systems and has resulted in strong national public health measures. the impact of the pandemic and its indirect environmental consequences on pediatric asthma is currently being assessed. in particular, the study of its role on the risk of exacerbations and modification of control is one of the priority research objectives defined by european societies. the primary aim is to study the impact of the pandemic on asthma control in children aged 3-16 years with a medical diagnosis of asthma, compared to data from other observational cohorts conducted in the same region prior to the pandemic. a sub-population of children 3-16 years will be assessed at exacerbation and at a follow-up visit, 2-4 months later, with clinical data, biological and microbiological samples.

children aged 3-16 years with a medical diagnosis of asthma, will be assessed for asthma control, exacerbation rate. data will be compared to data from other observational cohorts conducted in the same region prior to the pandemic. a sub-population of children 3-16 years will be assessed at exacerbation and at a follow-up visit, 2-4 months later, with clinical data, biological and microbiological samples.

Eligibility criteria:
inclusion criteria: * children and adolescents aged 3 to 16 years old * with a medical diagnosis of asthma as per-guidelines, who had been followed-up for at least 6 months, * assessed in one of the pediatric departments participating in the study, * after written consent of at least one of the 2 parents and/or representative of the parental authority, and of the child if he is older than 8 years old. criteria for the sub-population assessed at "exacerbation" and second visit: * children and adolescents aged 3 to 16 years * with a medical diagnosis of asthma as per-guidelines, who had been followed-up for at least 6 months, * hospitalized for a severe asthma exacerbation (requiring hospitalization and general corticosteroid therapy) at lille university hospital * after written consent of both parents and/or representative of the parental authority, and of the child if he is over 8 years old exclusion criteria: * history of chronic respiratory disease other than asthma, * inability of parents to receive informed information, inability to participate in the entire study, refusal to sign the consent form

Keywords: asthma control covid-19 pandemic respiratory infection environmental pollution
development of liquid biopsy technologies for noninvasive cancer diagnostics in patients with suspicious thyroid nodules or thyroid cancer

Conditions: Thyroid Gland Carcinoma; Thyroid Gland Nodule

Summary: this study is being done to help researchers learn more about and successfully diagnose cancer using blood samples and tissue samples from surgeries in patients with suspicious thyroid nodules or thyroid cancer. diagnosing cancer in this way, as opposed to biopsies, may be less invasive to the patient. analyzing blood and tissues samples may also help researchers to differentiate non-cancerous tumors from thyroid cancer and detect high-risk mutations to guide treatment.

primary objective: i. sensitivity and specificity of molecular profile of thyroid derived extracellular vesicles (evs) as predictor of thyroid cancer. secondary objectives: i. quantity of thyroid derived evs captured in various stages of thyroid cancer. ii. whether quantity of evs decreases in proportion to response to therapy in thyroid cancer patients. iii. optimal ribonucleic acid (rna)/deoxyribonucleic acid (dna) panel in thyroid tumor derived evs to diagnose thyroid cancer. outline: patients undergo collection of blood samples on the day of surgery following anesthesia but prior to incision and approximately 4-6 weeks after surgery. patients who undergo remnant ablation after total thyroidectomy with radioactive iodine have an additional blood sample collected. patients also undergo collection of tissue samples following surgical resection of the thyroid. patients' medical records are also reviewed.

Eligibility criteria:
inclusion criteria: * aged 18 and older * consented for thyroid surgery for thyroid cancer or indeterminate thyroid nodule exclusion criteria: * patients with concurrent malignancy
metformin in moderate and severe renal failure (ckd 3-4): a follow-up study

Conditions: Renal Insufficiency, Chronic

Summary: to validate on the mid-term in moderate and severe renal failure (ckd 3-4) a nomogram to adapt a fixed metformin daily posology according to renal function on the basis of the first short-term study made by the investigators.

a first open-label pilot study at different stages of ckd (1-5) (concerning whether or not metformin use is safe provided a dose adjustment is used) has evaluated (i) metformin levels in plasma and in erythrocytes according to an increasing metformin dosage and ckd severity (1-5) and (ii) the prevalence of lactate levels ≥2.5 mmol/l in ckd 3-5. all patients underwent 3 one-week- blocks of metformin treatment at an increasing dosage, each of which followed by a one week-wash- out period: 500 mg/day in the evening (e) in phase 1; 1,000 mg/day (500 mg morning (m) and e) in phase 2; 2,000 mg/day (1,000 mg m and e) in phase 3. steady-state trough blood levels were assayed 12 hours after the last dose of metformin. in this study a progressive dose-related increase of the trough metformin levels were observed and in particular in severe ckd stages. no case of severe hyperlactatemia was reported in this study. in continue, the investigators thought to conduct a new study to evaluate safety of metformin in mid-term period of time. for this purpose, metformin will be given at a fixed dose during 4 months: 1) 1,500 mg/day (500 mg m and 1,000 mg e) in stage 3a; 2) 1,000 mg/day (500 mg m and e) in stage 3b; and 3) 500 mg/day (m) in stage 4. metformin levels in plasma and in erythrocytes, venous lactate, and hba1c levels will be measured at 1, 2, 3 and 4 months for assessment of safety.

Eligibility criteria:
inclusion criteria: * type 2 diabetes patients with stable ckd stages 3a, 3b and 4 aged between 18 and 80 years requiring metformin (and any other antidiabetic treatment) exclusion criteria: * hyperlactatemia (\> 2.5 mmol/l) * no creatinine levels available since 3 months * severe hepatic insufficiency * no liver function parameters available * need of investigation with iodized contrast media * hypersensitivity to metformin

Keywords: metformin moderate renal failure severe renal failure chronic kidney disease hyperlactatemia lactic acidosis
medications for lower urinary tract symptoms secondary to benign prostatic hyperplasia

Conditions: Enlarged Prostate With Lower Urinary Tract Symptoms

Summary: the main objective of this prospective randomized controlled study is to compare safety and efficacy of vardenafil versus tadalafil versus tamsulosin in terms of (voiding function, sexual function and quality of life) in the management of moderate bph related luts.

this is prospective randomized controlled study that will be conducted on men with bph related luts amenable to medical treatment at urology department, faculty of medicine, tanta university - egypt after having their written informed consent. the study is planned to include 150 patients in the study period from april 2024 to april 2025. each enrolled patient must complete 12 weeks on medication with strict scheduled follow up. inclusion criteria: sexually active patients with moderate bph related luts amenable to medical treatment and completed 12 weeks follow up period. exclusion criteria: indication for combined therapy in patients who have moderate to severe luts and an increased risk of disease progression (e.g. prostate volume more than 40 ml) or patients in need for anti-muscarinic for predominant storage symptoms. indication for surgical intervention: medically complicated patients: cardiac patients, unstable angina, recent myocardial infarction (\<3months), hypotension. concomitant uses (potassium channel openers, alpha 1 blockers, nitrates). stroke since less than 6 months.

Eligibility criteria:
inclusion criteria: 1. sexually active patients . 2. moderatebph related luts ( bengin prostatic hyperplasia related lower urinary tract symtoms ) i.e: (international prostatic symptom score 8 to 19 : the higher score is the worse symptoms ). 3. patients accepted medical treatment and completed 12 weeks on medical treatment and strict follow up . exclusion criteria: 1. indication for combined therapy as prostate size over 40 gm . 2. gross hematuria. 3. refractory urine retention . 4. bilateral hydro-ureteronephrosis or renal insufficiency secondary to bengin prostatic hyperplasia. 5. bladder diverticula or calculi . 6. history of bladder or prostate cancer. 7. unwilling patients to medical therapy. 8. history of pelvic surgery or urethral stricture.
a study of jnj-90301900 in combination with chemoradiation followed by consolidation immunotherapy for non-small cell lung cancer (nsclc)

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the purpose of this study is to determine whether jnj-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (ccrt) followed by consolidation immunotherapy (cit) can improve objective response rate (orr; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage iii non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: * must be a candidate for standard of care (soc) treatment of non small cell lung cancer (nsclc) by concurrent platinum-based doublet chemotherapy with radiation therapy (ccrt) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening * have a medical history of pathologically (histologically or cytologically) proven diagnosis of nsclc within 3 months prior to enrollment/randomization * have locally advanced unresectable stage iiia or iiib nsclc according to the eighth edition lung cancer stage classification * have at least 1 target lesion (primary lung lesion or involved lymph node\[s\]) per recist version 1.1 that is amenable to intratumoral and/or intranodal injection and external beam radiation therapy (ebrt) as determined by the investigator at screening * have an eastern cooperative oncology group (ecog) performance status of 0 to 1 exclusion criteria: * medical history of: (a) primary immunodeficiency (b) organ transplant that requires therapeutic immunosuppression * any of the following within 3 months prior to enrollment/randomization: severe or unstable angina, myocardial infarction, major thromboembolic events, clinically significant ventricular arrhythmias or heart failure new york heart association functional classification class iii to iv * another concurrent or prior primary malignancy (other than nsclc) within the last 36 months at informed consent * known allergies, hypersensitivity, or intolerance to any ingredients of jnj-90301900 crystalline solution, platinum-based doublet chemotherapy (cht), or durvalumab * active bleeding diathesis or requirement for therapeutic anticoagulation or antiplatelet that cannot be interrupted or altered for procedures
effectiveness of hilt in shoulder osteoarthritis

Conditions: Osteoarthritis of the Shoulder

Summary: this study will determine the efficacy of high intensity laser therapy (hilt) for the treatment of shoulder osteoarthritis.

shoulder osteoarthritis (so) is a musculoskeletal joint disease that affects the elderly. so is characterized by degeneration of the articular cartilage in the involved joints and its underlying bone within a joint as well as bony overgrowth. it is one of the major causes of physical disability that has a social and public health impact due to pain, stiffness, joint instability, and muscle weakness. the diagnosed patients with so will be treated with hilt for a total of ten sessions during the entire duration of the treatment protocol. parameters to be evaluated are: range of motion, pressure pain (algometer), pain perception (visual analog scale (vas), modified laitinen pain questionnaire), quality of life (whoqol-bref) these parameters will be recorded before the first treatment (baseline), after completion of treatment, three and 12 months after completion treatment. a change in above parameters will be evaluated.

Eligibility criteria:
inclusion criteria: 1. painful osteoarthritis of the shoulder for at least 6 months 2. not engage in any other treatment during treatment period 3. pain ≥4 on the visual analog scale (vas) in the previous 3 months exclusion criteria: 1. presence of any other musculoskeletal problems associated with the shoulder joint, such as fracture, tendon or ligament tears, meniscus injury, rheumatoid arthritis, or shoulder surgery 2. receiving physical therapy and/or intra-articular corticosteroid or hyaluronic acid injections during the last 6 months 3. absolute and relative contraindications of laser therapy
evaluation of prevalence, molecular and genetic backgrounds of calcium-based stones among patients with renal calcular disease in mansoura urology and nephrology center

Conditions: Renal Calculi

Summary: evaluation of prevalence, molecular and genetic backgrounds of calcium-based stones among patients with renal calcular disease in mansoura urology and nephrology center

back ground: nephrolithiasis is a prevalent disease with high morbidity, the incidence and prevalence of nephrolithiasis has risen worldwide. calcium nephrolithiasis may be considered as a complex disease having multiple pathogenic mechanisms and characterized by various clinical manifestations. both genetic and environmental factors may increase susceptibility to calcium stones. polymorphisms of vitamin d receptor (vdr), calcium-sensing receptor gene (casr) and agxt have been associated with risk of urolithiasis, but, with inconsistent results and lack data from egyptian population. objective: therefore, the present study aims to investigate the prevalence, mutational profile for these genes in patients with ca-based stones, admitted to mansoura urology and nephrology center. methodology: in this study, employing sequencing of the coding exons of the calcium-sensing receptor gene (casr), vitamin d receptor (vdr) and agxt for a 50 of egyptian calcium kidney stone-formers and 20 control subjects. the results of the mutational profile data will be correlated with risk of stone recurrence over 2 years.

Eligibility criteria:
inclusion criteria: * all patients with unilateral or bilateral renal stones (de novo or recurrent) who were candidates for endoscopic or surgical intervention were included. metabolic workup was done for selected patients with radio-opaque stones, while genetic testing was done for those with dominant ca composition proven by postoperative stone analysis. thirty healthy individuals with no urologic abnormalities were involved as control cases. patients with renal calculi for whom metabolic and genetic testing were performed are designated "α" cases. exclusion criteria: * for metabolic and genetic testing, patients with a well-known lesion precipitating stone disease were excluded e.g. ureteric stricture, ureteropelvic or ureterovesical junction obstruction, urinary diversion, history of ureterovesical re-implantation as well as patients with non-ca stones by post-operative stone analysis

Keywords: renal calculi, renal ca oxalate stones, vdr gene
study of vesicare® in overactive bladder (oab) subjects to evaluate symptom bother and health related quality of life

Conditions: Urinary Bladder, Overactive

Summary: evaluate the effect of vesicare® on symptom bother for subjects with oab

phase 4, multi-center, randomized, double-blind, placebo-controlled, parallel group study. all subjects that meet the baseline criteria will be randomized in a 1:1 ratio into vesicare® (solifenacin succinate) or placebo group. the study duration consists of a screening period which includes a minimum of a 14 day treatment free wash-out period. subjects meeting the baseline criteria will have a 12 week treatment period. maximum total study duration is 15 weeks: 2 3 week screening / washout period; 12 week double-blind treatment. primary efficacy will be based on oab-q symptom bother score.

Eligibility criteria:
inclusion criteria: * ambulatory male or female subject ≥ 18 years of age and able to use the toilet without difficulty * history of oab symptoms for ≥ 3 months * an average of ≥ 8 micturitions per 24 hours and ≥ 1 urgency episode (with or without incontinence) per 24 hours as documented in a 3-day micturition diary * subjects are bothered by symptoms as reflected by ppbc ≥3 exclusion criteria: * evidence of chronic urologic inflammation such as interstitial cystitis and bladder stones; uncontrolled narrow angle glaucoma; urinary or gastric retention * recurrent urinary tract infection (uti) of \> 3 episodes within the last 3 months or evidence of a urinary tract infection at baseline visit (visit 2) * significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor as determined by the investigator * history of renal or hepatic impairment(2 x upper limit of normal(uln) values in parameters and considered clinically significant by the investigator * history of diagnosed gastrointestinal obstruction disease * subject has a known diagnosis or history of carcinoma (including prostate cancer) except non metastatic basal or squamous cell carcinoma of the skin that has been successfully treated or previous pelvis radiation within the past five years * known or suspected hypersensitivity to solifenacin succinate, any components, or other anticholinergics

Keywords: overactive bladder
diastology-guided management of decompensated heart failure

Conditions: Heart Failure; Diastolic Dysfunction

Summary: more than 30% of people hospitalized with decompensated heart failure return to the hospital within 90 days. emerging evidence suggests that hemodynamic monitoring with guided management may enhance prognosis and management. hemodynamic monitoring with echocardiography using diastology and an evidence-informed therapeutic protocol have the potential to achieve this aim in a minimally invasive manner.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years at the time of enrolment 2. decompensated heart failure with reduced ejection fraction (≤40%) 3. sinus rhythm without conduction abnormalities (second-degree mobitz ii, third-degree, permanent pacemaker) 4. written informed consent from either the patient or a substitute decision maker exclusion criteria: 1. mitral annular calcification (at least moderate or severe) 2. moderate or severe aortic or mitral valvular heart disease, or history of prosthetic mitral valve 3. atrial fibrillation or flutter 4. history of non-diagnostic echocardiogram 5. hemodialysis

Keywords: diastology echocardiography heart failure
performance of new diagnostic methods in older adults with pneumonia

Conditions: Pneumonia

Summary: create a clinical diagnostic pathway for older ed adults with pneumonia and its subgroups (bacterial, viral, and co-infection) and determine whether novel biomarkers improve diagnostic accuracy. the investigators will conduct a prospective observational trial of 250 ed patients ≥65 years old with suspected pneumonia. the investigators will perform analyses overall and by subgroups, seeking common models to ease adoption.


Eligibility criteria:
inclusion criteria: - adults aged 65 and older presenting to the ed with suspected pneumonia defined as (1) either a physician order for cxr or ct or a chief complaint consistent with dyspnea; and (2) physician suspicion of pneumonia prior to ed testing (score of 2-5 on likert scale) exclusion criteria: * inability to obtain consent from the patient or an lar * active cancer * organ transplant * immunosuppression * trauma activation * suicidal ideation * incarceration * antibiotics in the last 14 days * a separate episode of lower respiratory illness in the last 30 days
performance of 177lu-psma-i&t for rlt in mcrpc - prospective multicenter swiss registry study

Conditions: mCRPC

Summary: the goal of this observational study (multicenter, national registry-based) is to evaluate the performance of 177lu-itg-psma-1 (177lu-psma-i\&t) as therapy in patients with metastatic castration resistent prostate cancer (mcrpc). the main questions are whether the 177lu-psma-i\&t is safe and if it works well to treat patients with progressive mcrpc. the data and information in the study are collected under standard medical therapy and follow-up, so called real-world conditions. participants will: * undergo regular radioligand therapy (rlt) with 177lu-psma-i\&t * have clinical, laboratory and imaging follow-up according to the currently available recommendation for psma-rlt an in line with their medical needs. * answer study related set of questionnaires

prospective, multicenter swiss registry study evaluating the performance of 177lu-itg-psma-1 (177lu-psma-i\&t) as rlt in mcrpc. primary endpoint: safety- * frequency and severity of adverse events (measured according to ctcae 5.0). secondary endpoints: efficacy * biochemical response: best psa response, psa50 (\>50% decrease from baseline psa level) and psa response at 12 weeks * imaging response: objective response rate evaluated on follow-up morphological imaging ct/mri and/or on molecular imaging psma pet/ct * quality of life: evaluated with standardized questionnaires

Eligibility criteria:
inclusion criteria: * hormone-refractory and psma pet/ct-positive prostate tumors * progressed after or are ineligible for chemotherapy, next-generation antihormonal therapy or bone-directed radiation therapy -- male patients with an age above 18 years exclusion criteria: * patients who are not eligible for psma rlt, according to current, standard medical indications and guidelines * patients who for medical or non-medical reasons are unable to give their consent * patients withdrawing their consent for participation (nb: the already collected data in such cases will be anonymized and further used for applicable analyses)

Keywords: radioligand therapy 177lu-psma-i&amp;amp;t registry-study
painless myocardial ischemia in diabetic patients.

Conditions: Painless Myocardial Ischemia

Summary: this study aims to investigate the relationship between the concentrations of blood orphanin, norepinephrine and the morbidity of painless myocardial ischemia in patients with diabetes mellitus. hopefully, the biomarker(s) in the blood of diabetic patients can be found for screening high risk patients in the diabetes sufferers to prevent the painless myocardial ischemia.


Eligibility criteria:
inclusion criteria: * subject has diabetes exclusion criteria: * history of myocardial ischemia * symptoms of myocardial ischemia（ecg changes except）